P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from 'long vedo' italian multicenter study

Autor: G Mocci, G Maconi, F M Onidi, G Cataletti, W Elisei, F Scaldaferri, R Lorenzetti, C Pagnini, A Scarcelli, M G Graziani, M C Di Paolo, G Pranzo, I Luppino, R Monterubbianesi, R Faggiani, A Ferronato, E Savarino, R Pica, A Cocco, S Rodino, L Sebkova, C Zampaletta, F Gaiani, L Fanigliulo, L Allegretta, A Cuomo, L Donnarumma, N Della Valle, G Forti, E Antonelli, G Bassotti, C Iannelli, G Aragona, A Lauria, S Piergallini, R Colucci, L Binaghi, C Meucci, A Papa, A Tursi
Rok vydání: 2023
Předmět:
Zdroj: Journal of Crohn's and Colitis. 17:i635-i636
ISSN: 1876-4479
1873-9946
Popis: Background Current data about long-term use of vedolizumab (VDZ) in ulcerative colitis (UC) versus Crohn’s disease (CD) patients are limited. We aimed to assess whether there are differences in term of long-term efficacy and safety of VDZ in UC vs. CD patients. Methods Clinical activity was scored according to the Mayo score in UC and to the Harvey-Bradshaw Index (HBI) in CD. The primary endpoints were the achievement of clinical remission within 6 month of treatment, maintenance of clinical remission during a long follow-up, and safety. Secondary endpoints were clinical response to treatment, achievement of mucosal healing (MH), steroid discontinuation, and treatment optimization during the follow-up. Results The study group consisted of 729 patients (475 patients with UC and 254 CD patients with CD) with a median follow-up of 18 (interquartile range 6-36) months. Clinical remission at the 6th month of treatment was achieved in 488 (66.9%) patients, higher in CD patients (74.4 vs. 62.9, p Conclusion Overall, no significant differences were found about the long-term use of VDZ in UC vs. CD. However, we identified some parameters the can help the physician to predict the long-term efficacy of this drug.
Databáze: OpenAIRE
Externí odkaz: